Medication Management in Stage 4 CKD

Mandatory Discontinuations

The Kidney Disease: Improving Global Outcomes (KDIGO) guideline recommends discontinuing metformin when GFR falls below 30 mL/min/1.73 m² (stage 4-5 CKD) due to accumulation risk and potential for lactic acidosis 1, 2, 3, 4
The National Kidney Foundation recommends stopping all herbal remedies completely, as they lack safety data and have unpredictable nephrotoxic potential 1, 2, 5, 6
The American Diabetes Association recommends discontinuing first-generation sulfonylureas, such as chlorpropamide, tolazamide, and tolbutamide, immediately, as they accumulate dangerously in stage 4 CKD and cause prolonged half-lives and severe hypoglycemia risk 3, 4

The FDA recommends discontinuing NSAIDs in stage 4 CKD unless pain management alternatives have failed, due to the risk of acute kidney injury, electrolyte derangements, hypervolemia, and worsening heart failure/hypertension 1, 2
The Kidney Disease: Improving Global Outcomes (KDIGO) guideline recommends requiring intensive monitoring of drug levels, eGFR, and electrolytes if lithium is continued, and considering alternative mood stabilizers given the narrow therapeutic window and high nephrotoxicity risk 1, 2
The American Heart Association recommends dose reduction of digoxin, as renal clearance is impaired, and monitoring levels closely due to narrow therapeutic window and increased toxicity risk 1, 2

The Kidney Disease: Improving Global Outcomes (KDIGO) guideline recommends temporarily stopping ACE inhibitors, ARBs, aldosterone antagonists, diuretics, and SGLT2 inhibitors 48-72 hours before elective surgery or during acute illness that increases AKI risk 1, 2, 5, 6
The American Diabetes Association recommends reducing insulin doses by 25-50% and intensifying glucose monitoring to prevent severe hypoglycemia, as one-third of insulin degradation occurs in the kidneys and impaired renal function prolongs insulin half-life 3, 4

The American Diabetes Association recommends glipizide as the preferred second-generation sulfonylurea, as it lacks active metabolites and doesn't increase hypoglycemia risk in CKD, and reducing doses of glyburide and glimepiride due to active metabolite accumulation 3, 4
The European Association for the Study of Diabetes recommends starting with low doses of repaglinide and nateglinide at meals and titrating cautiously when GFR <30 mL/min/1.73 m² 3, 4

The National Kidney Foundation recommends avoiding all OTC NSAIDs, such as ibuprofen and naproxen, due to the risk of acute kidney injury and worsening kidney function 1, 2
The Kidney Disease: Improving Global Outcomes (KDIGO) guideline recommends avoiding nutritional protein supplements without medical supervision, due to the risk of hyperphosphatemia and worsening kidney function 1, 2

The Kidney Disease: Improving Global Outcomes (KDIGO) guideline recommends performing comprehensive medication reconciliation, reviewing all prescriptions, OTC medications, supplements, and herbal products, and assessing continued indication for each medication 5, 6
The American Society of Nephrology recommends establishing collaborative care, engaging clinical pharmacists for medication management, coordinating with all prescribing specialists, and using drug stewardship tools designed for CKD patients 5, 6
The National Kidney Foundation recommends monitoring closely, checking eGFR, electrolytes, and therapeutic drug levels regularly, and increasing monitoring frequency during transitions of care 5, 1, 2